| human | Q5 |
| P496 | ORCID iD | 0000-0001-9366-775X |
| P69 | educated at | Mayo Clinic | Q1130172 |
| P108 | employer | Mayo Clinic | Q1130172 |
| P734 | family name | Burton | Q1259568 |
| Burton | Q1259568 | ||
| Burton | Q1259568 | ||
| P735 | given name | Duane | Q3715637 |
| Duane | Q3715637 | ||
| P106 | occupation | researcher | Q1650915 |
| Q35028313 | A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea |
| Q37069091 | A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults |
| Q34324881 | A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function |
| Q34007516 | A preliminary candidate genotype-intermediate phenotype study of satiation and gastric motor function in obesity |
| Q37585280 | A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation |
| Q44097544 | A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation |
| Q39383290 | A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome |
| Q37086144 | A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research |
| Q47285304 | Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine |
| Q36756795 | Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome |
| Q57117342 | Analysis of Fecal Primary Bile Acids Detects Increased Stool Weight and Colonic Transit in Patients With Chronic Functional Diarrhea |
| Q36494385 | Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea |
| Q35235956 | Association of UCP-3 rs1626521 with obesity and stomach functions in humans |
| Q37669824 | Association of melanocortin 4 receptor gene variation with satiation and gastric emptying in overweight and obese adults |
| Q37185328 | Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome |
| Q36846477 | Candidate genes and sensory functions in health and irritable bowel syndrome |
| Q36699687 | Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits |
| Q24635181 | Chenodeoxycholate in Females With Irritable Bowel Syndrome-Constipation: A Pharmacodynamic and Pharmacogenetic Analysis |
| Q35844591 | Clinical Features and Colonic Motor Disturbances in Chronic Megacolon in Adults |
| Q39179801 | Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption |
| Q37231289 | Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? |
| Q34765145 | Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health |
| Q43352181 | Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome |
| Q34399520 | Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study |
| Q37100282 | Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects |
| Q34269632 | Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome |
| Q51500341 | Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. |
| Q34025992 | Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity |
| Q46761185 | Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study |
| Q43105627 | Effect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans |
| Q47301922 | Effect of different macronutrients in excess on gastric sensory and motor functions and appetite in normal-weight, overweight, and obese humans |
| Q46761195 | Effect of gastric volume or emptying on meal-related symptoms after liquid nutrients in obesity: a pharmacologic study |
| Q51318198 | Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea. |
| Q33977333 | Effect of meal ingestion on ileocolonic and colonic transit in health and irritable bowel syndrome |
| Q47216631 | Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers |
| Q39375148 | Effect of renzapride on transit in constipation-predominant irritable bowel syndrome |
| Q35159654 | Effect of the α2δ ligand, pregabalin, on colonic sensory and motor functions in healthy adults |
| Q51368980 | Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. |
| Q57119544 | Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial |
| Q36970524 | Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome |
| Q48223585 | Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study |
| Q33426587 | Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans |
| Q24647522 | Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function |
| Q46711621 | Effects of desipramine and escitalopram on postprandial symptoms induced by the nutrient drink test in healthy volunteers: a randomized, double-blind, placebo-controlled study |
| Q47185132 | Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial |
| Q44797399 | Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans |
| Q24684839 | Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome |
| Q36248001 | Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study |
| Q57792182 | GI Dysfunctions in Diabetic Gastroenteropathy, their Relationships with Symptoms, and Effects of a GLP-1 antagonist |
| Q47314674 | Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people |
| Q47820065 | Gastric sensory and motor dysfunction in adolescents with functional dyspepsia |
| Q34131127 | Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion |
| Q46930478 | Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation |
| Q34949021 | HLA-DQ genotype is associated with accelerated small bowel transit in patients with diarrhea-predominant irritable bowel syndrome |
| Q35195049 | Increased nutrient sensitivity and plasma concentrations of enteral hormones during duodenal nutrient infusion in functional dyspepsia |
| Q34603143 | Mitochondrial DNA and gastrointestinal motor and sensory functions in health and functional gastrointestinal disorders |
| Q33618369 | Neuropeptide S receptor induces neuropeptide expression and associates with intermediate phenotypes of functional gastrointestinal disorders |
| Q51478679 | Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults. |
| Q51485668 | Obesity does not increase effects of synthetic ghrelin on human gastric motor functions. |
| Q36487263 | Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations |
| Q28244460 | Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome |
| Q37259375 | Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea |
| Q36877142 | Pilot study of pyridostigmine in constipated patients with autonomic neuropathy |
| Q37624734 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome |
| Q36808881 | Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome |
| Q35118214 | Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy |
| Q34298494 | Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics |
| Q37270032 | Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation |
| Q51022617 | Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial. |
| Q47739420 | Relationship of gastric emptying or accommodation with satiation, satiety, and postprandial symptoms in health |
| Q33665390 | Reproducibility and performance characteristics of colonic compliance, tone, and sensory tests in healthy humans |
| Q37248624 | The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus |
| Q35562079 | Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls |
Search more.